Human Ephrin-A4/EFNA4 Protein
Catalog No: EFNA4-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human Ephrin-A4/EFNA4 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Leu26-Gly171 (UniProt accession: P52798-1).
Product Details
- Molecular Aliases
- Ephrin-A4; Ephrin A4; LERK-4; EFNA4; EPLG4; EFL4;LERK4
- Protein Length
- Leu26-Gly171
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 43.1 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human Ephrin-A4 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human Ephrin-A4 is greater than 95% as determined by SEC-HPLC.
Immobilized Human EphA7, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Human Ephrin-A4, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA (QC Test).
Background
Ephrin A4 is one of the ephrin ligand molecules belonging to the tyrosine kinases receptor family. It was originally identified in a T-lymphoma cell line and seen to be expressed in human adult tissue as well as several tumor types. The cytoplasmic pattern of ephrin A4 could identify a subgroup of primary osteosarcoma patients with a high liability for progression, poor prognosis, and inferior response to chemotherapy.
References
- Abdou AG, Abd el-Wahed MM, Asaad NY, Samaka RM, Abdallaha R. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome. Indian J Cancer. 2010 Jan-Mar;47(1):46-52. doi: 10.4103/0019-509X.58859. PMID: 20071790.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.